How AI Search Is Recommending Medical Billing Services: Monthly Trends

Executive Summary

athenahealth remains the category leader in October 2026 with 54.3% valid recommendation coverage, extending its lead over second-place Tebra (Kareo), at 38.6%, to 15.7 points. The lead widened from 9.0 points in July 2026 to its current level as the leader recovered from a September 2026 pullback while the second-place brand also recovered but by less. The category was mixed rather than uniform this month: two brands posted significant baseline-to-current gains, one posted a significant decline, and the remaining seven held within normal variation.

The strongest structural riser against the July 2026 baseline is eClinicalWorks, whose valid recommendation coverage rose 5.6 points from 22.2% in July 2026 to 27.8% in October 2026. That increase was significant, and it was accompanied by significant baseline-to-current gains in raw mention presence, rising from 49.9% to 61.1%, in top-three recommendation rate, rising from 6.8% to 11.2%, and in rank-one rate, rising from 0.0% to 1.5%. R1 RCM is the second significant baseline-to-current riser, up 4.2 points from 11.2% in July 2026 to 15.4% in October 2026, with significant supporting gains in presence, top-three rate, and rank-one rate.

The sharpest decliner is CureMD, down 8.8 points from 21.0% in July 2026 to 12.2% in October 2026, a significant decline that has now widened for three consecutive months. CureMD's valid recommendation coverage has fallen from 21.0% to 17.3% to 12.6% to 12.2% across the series, and its raw mention presence fell 10.0 points over the same span, from 25.7% to 15.7%.

Against the prior month of September 2026, the October result is best described as a partial recovery at the top. athenahealth rose 10.1 points from 44.2% in September 2026 to 54.3% in October 2026, and AdvancedMD rose 7.3 points from 30.6% to 37.9%, both significant prior-to-current moves. Those gains partially offset the September declines in the leading group. The category's mid-table remains clustered, and the benchmark shows the top positions separating from the rest.

Each monthly run begins with 800 prompt-surface observations (419 unique questions in July 2026 versus 488 in October 2026) across the benchmark's defined AI/search surface universe. Of those, 800 mentioned a tracked brand or competitor in each month; 747 were relevant and 53 were irrelevant in July 2026, versus 749 relevant and 51 irrelevant in October 2026. The public metrics use the 571 qualified observations in July 2026 and the 591 qualified observations in October 2026 that survive both qualification stages.

Key Findings

AI Response Inconsistency Alerts

Questions This Section Answers

• Which pricing claims about medical billing services conflicted across AI platforms?
• Where did AI platforms disagree about who owns or operates a medical billing vendor?

The benchmark detected 9 critical or high severity factual inconsistencies across 5 AI platforms in the current measurement window. Each conflict below represents a case where two AI platforms gave incompatible answers to the same question, with high confidence that the claims cannot both be correct.

AdvancedMD

Four high severity pricing inconsistencies were detected for AdvancedMD. On the question "How much does AdvancedMD cost?", ChatGPT stated that setup and onboarding fees range from free to $1,000 for smaller practices and up to $6,000 for more complex implementations, citing the company's own pricing page, while Copilot stated a fixed implementation and training range of $1,000 to $5,000, citing third-party pricing guides. The lower and upper bounds of these two claims do not match.

On the same cost question, Google AI Overviews stated that data migration costs an estimated $800 to $5,000 or more, citing AdvancedMD's pricing and news pages plus a third-party guide, while Copilot stated a data migration range of $500 to $2,000, citing two third-party pricing sites. The two ranges do not overlap.

On the question "How much is AdvancedMD a month?", Copilot stated that a practice management only plan starts at $429 per provider per month, while Perplexity stated that a basic practice management only configuration is around $130 per provider per month. The two platforms appear to have generalized from different specialty tiers. The flagged source pages show that AdvancedMD's own pricing page lists differentiated specialty pricing, with medical specialties at $429 to $1,070 per provider per month and mental health at $130 to $399 per provider per month.

On the same monthly pricing question, Copilot stated that a full suite EHR plus practice management configuration is $729 per provider per month, while Perplexity stated that the same combination is around $429 per provider per month. A flagged third-party page notes that configurations land around $429, $729, or higher depending on modules, which is consistent with the conflicting ranges rather than resolving them.

athenahealth

Two high severity inconsistencies were detected for athenahealth. On the question "What is the best EMR for small medical practices?", ChatGPT stated that athenahealth generally uses a customized pricing model tied to its services rather than a simple monthly list price, while Copilot stated that athenahealth pricing is approximately $140 per provider per month. A flagged source page on the Copilot side lists an RCM-led billing configuration at $140 per provider per month, while a flagged source on the ChatGPT side notes that roughly half of EHR vendors publish no price at all.

On the question "What are the major RCM companies in healthcare?", Perplexity stated that athenahealth is now part of Veradigm, while ChatGPT described athenahealth as an independent cloud EHR and integrated billing and revenue cycle management company with no parent mentioned. The benchmark treats these as incompatible: a company cannot simultaneously be part of Veradigm and be an independent vendor with no parent.

CareCloud

One high severity pricing inconsistency was detected for CareCloud. On the question "How much does CareCloud cost?", ChatGPT stated that CareCloud PRIME starts at $249 per provider per month, citing the company's own product page, while Copilot stated that CareCloud pricing starts at $349 per provider per month for its entry-level Central plan, citing third-party review sites. A flagged third-party pricing page lists CareCloud at $349 per provider per month. Both platforms presented their figure as the entry-level price, which cannot both be correct.

DrChrono

One high severity factual inconsistency was detected for DrChrono. On the question "Is DrChrono legit?", Google AI Overviews stated that DrChrono is owned by EverHealth, while Copilot stated that DrChrono is owned by EverCommerce, described as a publicly traded company. EverHealth and EverCommerce are different parent entities, so both claims cannot be true. A flagged third-party review page on the Copilot side lists ownership as EverCommerce, while a flagged source page indexed to both sides describes a relationship between EverHealth and EverCommerce without resolving which entity is the direct parent.

Tebra (Kareo)

One high severity factual inconsistency was detected for Tebra (Kareo). On the question "What is the easiest medical billing software?", Gemini stated that Kareo is branded as Tebra, while Perplexity stated that Tebra is in the CareCloud family. Tebra and CareCloud are separate companies, so the two claims cannot both be correct. Two flagged source pages on the Gemini side describe Tebra as formerly Kareo and list it as a standalone product, which supports the rebranding claim rather than the CareCloud association.

Benchmark Context

The report separates the raw collection universe from the qualified analysis set. Brand-level recommendation percentages are calculated within the qualified benchmark set.

The qualified surface breadth stayed at the maximum of six families across the series, meaning no surface family dropped out of the qualified set at any point between July 2026 and October 2026.

Benchmark-Level Metrics

The recommendation-shaped answer share did not move in a straight line. It fell to 33.2% in August 2026 and 30.1% in September 2026 before rebounding to 47.7% in October 2026, which is above the July 2026 baseline. The valid recommendation shortlist share followed a similar shape, dipping to 52.7% in August 2026 and 50.3% in September 2026 before rising to 61.6% in October 2026. The benchmark cannot establish why AI systems returned to more shortlist-style answers in October 2026.

AI Recommendation Trend

Questions This Section Answers

• Who leads in valid recommendation coverage, and how wide is the gap over the rest of the field?
• Which medical billing brands moved significantly over the series, and in which direction?

The leader sits alone at the top while the middle of the table compresses into a tight band and the bottom stays thin. athenahealth holds first place with a double-digit gap over the field, and the largest structural movements over the series came from brands outside the top two.

Valid Recommendation Coverage by Brand

Two brands exceeded normal month-to-month variation across the baseline-to-current comparison, both on the upside: eClinicalWorks and R1 RCM. One brand exceeded it on the downside: CureMD. The category-level improvement came from the combination of several smaller upward movements plus a significant prior-to-current rebound in the two leaders, not from a single brand's change.

What Changed This Month

Questions This Section Answers

• Why did athenahealth's rebound to a new series high come from placements rather than presence?
• What separates Tebra (Kareo)'s rank-one erosion from its stable shortlist breadth?
• Which medical billing brand declined most, and was the drop driven by presence or placement?

athenahealth: Leader Rebounds to a New Series High

athenahealth's valid recommendation coverage rose 4.0 points from 50.3% in July 2026 to 54.3% in October 2026, and the sharper move is the prior-to-current one: up 10.1 points from 44.2% in September 2026, a significant recovery after two consecutive months of decline.

Placement measures moved with coverage. Top-three recommendation rate rose from 36.4% to 41.6%, and rank-one rate rose from 15.2% to 18.1%. The valid recommendation count rose from 287 in July 2026 to 321 in October 2026.

The distinction to notice: athenahealth's coverage gains came from converting an almost universal presence into shortlist placements rather than from expanding where it appears, since raw mention presence was already near saturation at 89.3% in July 2026 and reached 91.5% in October 2026. Highest-priority diagnostic: Which prompt contexts held athenahealth's presence steady while previously withholding a placement, and what changed in those contexts between September 2026 and October 2026?

Tebra (Kareo): Second Place, Narrowing Lead Over Third

Tebra (Kareo)'s valid recommendation coverage slipped 2.7 points from 41.3% in July 2026 to 38.6% in October 2026, a move within normal variation. The prior-to-current move was up 4.6 points from 34.0% in September 2026, not significant on its own.

Placement detail separates from coverage here. Top-three recommendation rate fell from 22.2% to 20.0%, a minor change, but rank-one rate fell 5.7 points from 12.3% to 6.6%, a significant decline. The valid recommendation count slipped from 236 in July 2026 to 228 in October 2026, while raw mention presence held essentially flat at 58.5% versus 58.4%.

The distinction to notice: Tebra (Kareo) retained its presence and most of its shortlist breadth but lost roughly half of its first-position placements over the series, and its cushion over third-place AdvancedMD narrowed to 0.7 points in October 2026. Highest-priority diagnostic: Which surfaces and prompt types carried the rank-one placements that Tebra (Kareo) lost, and which brand occupies that slot in October 2026?

AdvancedMD: Significant Prior-to-Current Rebound

AdvancedMD's valid recommendation coverage fell 2.4 points from 40.3% in July 2026 to 37.9% in October 2026, a move within normal variation. The sharper story is the prior-to-current move: up 7.3 points from 30.6% in September 2026, a significant rebound from the September trough.

Rank-one rate rose significantly against the baseline, from 2.3% to 5.9%, even as top-three rate was essentially flat at 23.3% versus 24.2%. Raw mention presence rose from 53.2% to 57.0%. The valid recommendation count slipped from 230 in July 2026 to 224 in October 2026.

The distinction to notice: AdvancedMD's rank-one rate is the highest it has been in the series, which indicates its shortlist placements are landing higher even though the total count is similar, despite coverage against July 2026 being slightly lower. Highest-priority diagnostic: Which prompts produced the additional first-position placements in October 2026, and does the pattern hold across surfaces?

eClinicalWorks: Significant Riser on Presence and Placement

eClinicalWorks' valid recommendation coverage rose 5.6 points from 22.2% in July 2026 to 27.8% in October 2026, a significant increase and the strongest baseline-to-current rise in the category.

Every supporting measure also rose significantly against the baseline. Raw mention presence rose 11.2 points from 49.9% to 61.1%. Top-three recommendation rate rose from 6.8% to 11.2%. Rank-one rate rose from 0.0% in July 2026 to 1.5% in October 2026, meaning the brand moved from no first-position placements to a measurable share. The valid recommendation count rose from 127 in July 2026 to 164 in October 2026.

The distinction to notice: eClinicalWorks gained on both presence and placement, which separates it from brands whose presence grew without converting into shortlist inclusion. Highest-priority diagnostic: Which prompts produced the new rank-one placements from a zero base, and which competitor held those slots in July 2026?

CureMD: Significant Decline on a Three-Month Downtrend

CureMD's valid recommendation coverage fell 8.8 points from 21.0% in July 2026 to 12.2% in October 2026, a significant decline, and the series shows a steady erosion across all four months: 21.0% to 17.3% to 12.6% to 12.2%. The prior-to-current move of 0.4 points was within normal variation, so October confirms the lower level rather than extending the drop sharply.

Raw mention presence fell significantly against the baseline, down 10.0 points from 25.7% to 15.7%, and the decline was stepwise across the series. Top-three rate held near flat at 4.4% versus 4.2%, and rank-one rate was near flat at 1.4% versus 1.0%. The valid recommendation count fell from 120 in July 2026 to 72 in October 2026.

The distinction to notice: CureMD lost both presence and coverage, which means it is being mentioned less often overall and converting fewer of those mentions into placements. Its decline is broader than a placement-only shift. Highest-priority diagnostic: Which prompt contexts stopped mentioning CureMD entirely, and which evidence sources previously surfaced the brand in those contexts?

R1 RCM: Significant Riser on Rank-One Strength

R1 RCM's valid recommendation coverage rose 4.2 points from 11.2% in July 2026 to 15.4% in October 2026, a significant increase. The prior-to-current move of 2.8 points from September 2026 was within normal variation, so the gain accumulated across the second half of the series: 11.2% to 8.7% to 12.6% to 15.4%.

Supporting measures moved significantly against the baseline. Raw mention presence rose from 14.4% to 18.8%. Top-three recommendation rate rose from 4.5% to 9.1%. Rank-one rate rose from 1.6% to 5.8%, a significant increase. The valid recommendation count rose from 64 in July 2026 to 91 in October 2026.

The distinction to notice: R1 RCM's placement gains were steeper than its presence gains, meaning the brand is winning higher positions within answers where it appears rather than only appearing more often. Highest-priority diagnostic: Which prompts produced the added top-three and rank-one placements, and which brands lost those positions?

CareCloud and DrChrono: A Rising Mid-Table Brand and a Retreating One

CareCloud's valid recommendation coverage rose 3.1 points from 14.7% in July 2026 to 17.8% in October 2026, within normal variation overall, and it now carries a two-month upward streak. Top-three rate rose significantly against the baseline, from 3.7% to 7.8%, and raw mention presence rose from 19.3% to 22.7%. The valid recommendation count rose from 84 in July 2026 to 105 in October 2026.

DrChrono's coverage fell 4.5 points from 28.9% in July 2026 to 24.4% in October 2026, within normal variation, but the brand carries a two-month upward streak from the August 2026 low of 20.9%. Its raw mention presence held essentially flat at 39.9% versus 40.3%, and its valid recommendation count slipped from 165 in July 2026 to 144 in October 2026.

The distinction to notice for both brands: CareCloud converted a modest presence gain into a significant top-three placement gain, while DrChrono recovered coverage faster than presence, which indicates a change in how its existing mentions are being ranked rather than in how often it is cited. Highest-priority diagnostic for CareCloud: Which prompts drove the new top-three placements? Highest-priority diagnostic for DrChrono: Where did the loss of 21 valid recommendations between July 2026 and October 2026 occur?

Greenway Health and Medusind: Small-Count Signals

Greenway Health's valid recommendation coverage rose 1.2 points from 1.8% in July 2026 to 3.0% in October 2026, a move within normal variation and on small counts. Raw mention presence rose significantly against the baseline, from 3.3% to 8.0%, while top-three rate stayed near zero at 0.2% versus 0.3%. The valid recommendation count rose from 10 in July 2026 to 18 in October 2026.

Medusind's coverage was unchanged at 0.2% from July 2026 to October 2026, on valid recommendation counts of 1 in July 2026 and 1 in October 2026. Raw mention presence edged from 0.7% to 0.5%, with presence counts of 4 in July 2026 and 3 in October 2026.

The distinction to notice for both brands: these are very small absolute counts and the movements are directional only. Greenway Health's presence growth is the more notable signal because mentions are expanding faster than shortlist inclusion. Highest-priority diagnostic for Greenway Health: In which contexts is the brand mentioned without being recommended? Highest-priority diagnostic for Medusind: Which prompt produced the single valid recommendation in October 2026, and what evidence source surfaced it?

Buyer-Intent Interpretation

Questions This Section Answers

• What type of buyer questions did the qualified benchmark actually capture in October 2026?
• Why can't the benchmark measure pricing, value, and head-to-head comparison questions that buyers ask?

In October 2026, all qualified observations in this vertical again fell into the brand recommendation cluster. The benchmark found no qualified observations in the pricing and value cluster or the multi-brand comparison cluster in any month of this series. The response-type distribution shows pricing analysis answers were present in the raw collection, at 17 in October 2026 versus 12 in July 2026, and comparison analysis answers were present at 42 in October 2026 versus 40 in July 2026, but neither class qualified as valid recommendation observations.

The commercial consequence is direct: the public benchmark can measure which brands AI systems recommend and how placement shifts month to month, but it cannot yet answer the pricing, value, and head-to-head comparison questions that buyers bring to these systems. The AI Response Inconsistency Alerts section above shows that pricing answers are being produced and that they conflict across platforms, which makes the gap between what AI systems say about price and what the benchmark can measure commercially significant.

Brand Opportunity Summary

Questions This Section Answers

• Which medical billing brands carry the strongest recommendation signal, and what should each investigate next?

The benchmark identifies where attention is warranted; a company-level analysis is needed to explain why.

Evidence Behind the Benchmark

The aggregate metrics are built from prompt-level observations (query, surface, recommendation outcome, rank, sentiment, and citations where exposed). Company-level analysis can go deeper into prompt, competitor, surface, and evidence patterns. Source presence is not automatically treated as proof of causation.

About This Benchmark

This report is part of the CiteWorks Studio AI Visibility Industry Market research program.

• AI Visibility Industry Market Index
• AI Visibility Industry Market Methodology
• AI Visibility Industry Market Metrics
• AI Visibility Industry Market Standards

Report-Specific Interpretation Notes

• Movement between months identifies changes worth investigating; it does not by itself establish the cause of those changes.
• Small-count brands (Greenway Health, Medusind) carry higher uncertainty; their movements are directional signals, not conclusive trends.
• The qualified benchmark set (571 in July 2026, 591 in October 2026) is smaller than the raw collection (800); percentages are calculated within the qualified set.
• Changes in recommendation-shaped answer share and response-type mix may make coverage comparisons more complex, independent of any single brand's performance.

Next Step

The Public Benchmark Shows Where a Brand Is Winning or Losing. A Company-Level Audit Shows Why.

Beneath the aggregate percentages lie the questions that matter for competitive position: which high-intent prompts are won, which competitor takes the recommendation when a brand loses, what attributes AI systems associate with each option, and which external sources shape those answers. The benchmark shows a category where the top two leads belong to athenahealth by a widening margin, two mid-table brands are rising significantly, and one brand is in a three-month decline, but it does not explain what is driving those AI shortlist decisions.

A company-specific AI visibility audit maps those prompt, surface, competitor, ranking, sentiment, and evidence-source patterns into a prioritized visibility strategy. Where the benchmark tells you what changed, a company-level audit tells you why, and what to do about it.

Request an AI visibility audit